Clinical Trial Update: Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating gabexate mesilate for hepatocyte protection after liver resection was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease

Drugs mentioned

• Gabexate mesilate (gabexate mesilate)

Snippet

Sponsor: Yonsei University | Conditions: Liver Disease | Phase 3 | Status: TERMINATED